CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application

Approximately 25 % of clinically important drugs and numerous environmental carcinogens are metabolised by CYP2D6. Variation in the CYP2D6 gene and concomitant use of tamoxifen (TAM) with certain antidepressants may increase recurrence risk in breast cancer patients due to reduced enzyme activity. I...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Merwe, Nicole, Bouwens, Christianne S. H., Pienaar, Rika, van der Merwe, Lize, Yako, Yandiswa Y., Geiger, Dieter H., Kotze, Maritha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505529/
https://www.ncbi.nlm.nih.gov/pubmed/22638694
http://dx.doi.org/10.1007/s11011-012-9312-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505529/
https://www.ncbi.nlm.nih.gov/pubmed/22638694
http://dx.doi.org/10.1007/s11011-012-9312-z

Ejemplares similares